THERAPEUTICS
High-concentration capsaicin reduced pain in patients with HIV-associated polyneuropathy
| The first 150 words of the full text of this article appear below. |
D M Simpson
Dr D M Simpson, Mount Sinai Medical Center, New York, NY, USA; david.simpson@mssm.edu
STUDY DESIGN
randomised controlled trial.
unclear concealment.*
blinded {patients and investigators}
.*
STUDY QUESTION
30 centres in the USA.
307 patients (mean age 48 y, 93% men) who had
2 months of moderate to severe neuropathic pain in both feet (mean Numeric Pain Rating Scale [NPRS] screening score of 3–9) secondary to HIV-associated distal sensory polyneuropathy or neurotoxic antiretroviral treatment. Treatment dose had to be stable for
8 weeks for current antiretroviral drugs and
21 days for other pain medications. Exclusion criteria included use of topical analgesics; pain other than HIV-associated neuropathy; cardiac, renal, hepatic, or pulmonary function abnormalities; hypersensitivity to capsaicin or opioids; and use of
60 mg morphine-equivalent.
225 patients were allocated to a single application of a high-concentration capsaicin dermal patch (640 mcg/cm2, 8% w/w), and 82 were allocated to a low-concentration (control) patch
Vanderbilt University, Nashville, Tennessee, USA
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
